Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium,Blood Cancer Journal

当前位置： X-MOL 学术 › Blood Cancer J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
Blood Cancer Journal ( IF 12.8 ) Pub Date : 2024-04-12 , DOI: 10.1038/s41408-024-00993-0
Aimaz Afrough , Hamza Hashmi , Doris K. Hansen , Surbhi Sidana , Chul Ahn , Lauren C. Peres , Danai Dima , Ciara L. Freeman , Omar Castaneda Puglianini , Mehmet H. Kocoglu , Shebli Atrash , Peter M. Voorhees , Leyla Shune , Joseph P. McGuirk , Gary Simmons , Douglas W. Sborov , James A. Davis , Gurbakhash Kaur , Aishwarya Sannareddy , Christopher J. Ferreri , Mahmoud R. Gaballa , Scott Goldsmith , Omar Nadeem , Shonali Midha , Charlotte B. Wagner , Frederick L. Locke , Krina K. Patel , Jack Khouri , Larry D. Anderson , Yi Lin